#Most frequent potentially immune-related adverse events during nivolumab were endocrinopathies (all grades 1–2), including hyperthyroidism (11.9%), hypothyroidism (14.3%), adrenal insufficiency (2.4%), and ACTH decrease (4.8%) [18]. The gene discussed is POMC; the disease is hyperthyroidism.